Synapse - Martin Tallman

Results (14)

Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia

Journal Article

Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
NEJM Evidence (2023)

Fulltext@MSK | Save

First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL

Meeting Abstract

Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
Blood (2021)

Fulltext@MSK | Save

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

Journal Article

Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
Leukemia and Lymphoma (2021)

Fulltext@MSK | Save

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Journal Article

Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Daniyan, A. F.; Famulare, C.; Cuello, B. M.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
Blood (2020)

Fulltext@MSK | Save

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: A single-centre, single-arm, phase 2 trial

Journal Article

Taylor, J.; Mi, X.; Penson, A. V.; Paffenholz, S. V.; Alvarez, K.; Sigler, A.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; more...
The Lancet Haematology (2020)

Fulltext@MSK | Save

First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL

Meeting Abstract

Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
Blood (2019)

Fulltext@MSK | Save

Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents